Launch of new products suggests Medtronic’s success
Investment idea by DTI Algorithmic
Exchange: NYSE
Sector: Healthcare
Industry: Medical Appliances & Equipment
Entry strategy
Price: $88–91
Stop-loss: under $83,22
Take profit: $108,5
Investment horizon: half a year
Company details
Medtronic plc ($MDT) is one of the largest manufacturers of medical equipment. In 2015, Medtronic, Inc. acquired Covidien plc ($COV). Under the terms of the contract, they merged into Medtronic plc. The company is headquartered in Dublin, Ireland.
Medtronic has six main business units that develop treatments for more than 70 chronic diseases, including heart failure, Parkinson’s disease and diabetes:
- heart rhythm disorders
- neuromodulation,
- spinal surgery,
- diabetes,
- heart surgery,
- surgical navigation technology.
The issuer’s capitalization is more than $124.5 billion (group + Large).
Company financial performance
The first two quarters of 2018 proved to be financially successful for Medtronic. Regular market launch of new products and services is any corporation’s key to success for increasing its value.
Medtronic financial performance
At the end of October, 2018, the company received the approval of the U.S. Food and Drug Administration (FDA) on
- a new system of aortic lesions repairment Valiant Navion(TM) — it allows patients with small iliac arteries to receive treatment;
- a product for patients with chronic pain SynchroMed(TM)II myPTM(TM) Personal Therapy Manager — the device facilitates unpredictable pain by delivering automatic injections of drugs and painkillers prescribed by a doctor.
Technical analysis (trading plan)
Originally published at Блог DTI Algorithmic.
